FTC Wants To Extend Actavis To Authorized Generics Deals

Law360, New York (August 16, 2013, 7:05 PM EDT) -- The Federal Trade Commission on Wednesday urged a New Jersey federal judge overseeing private antitrust litigation targeting an authorized generics deal between Wyeth LLC and Teva Pharmaceuticals USA Inc. to apply the U.S. Supreme Court's recent pay-for-delay ruling to the case.

The FTC sought permission to file an amicus curiae brief arguing that a promise by a branded drugmaker not to launch its own authorized generic version of a drug during a generics company's exclusivity period functioned the same way that straight payments to generic-drug makers...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.